 Austin, Texas, March 17, 2021 GLOBE NEWSWIRE -- QSAM Biosciences, Inc. OTCQB: QSAM announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a worldwide, exclusive license agreement for a pre-clinical staged radiochemical therapy called BetaBrachTM. 